Evidence mapPaperPMID 34780485Full record

ArticlePloS one2021

Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies.

David M Nathan, Heidi Krause-Steinrauf, Barbara H Braffett, Valerie L Arends, Naji Younes, Paula McGee, Claire Lund, Mary Johnson, Gayle Lorenzi, Xiaoyu Gao and 4 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01794143. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01794143 phase3completed

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study

Ran2013Enrolled7,850Registered outcomes4Posted comparisons0ConditionsComparative Effectiveness of Glycemia-lowering Medications, Type 2 DiabetesArmsDPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine), Sulfonylurea (glimepiride)
Open the trial in the graph
NCT02388100 completednot on this map

The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study) Capillary Blood Collection: A Pilot Study

TypeobservationalSponsorGRADE Study GroupRan2015 to 2016Enrolled70ConditionsType 2 DiabetesArmsCapillary HbA1c collection
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.The New England journal of medicine · 2022 · on this map
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

David M NathanMassachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.
Heidi Krause-SteinraufThe Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.ORCID 0000-0001-6894-4110
Barbara H BraffettThe Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Valerie L ArendsAdvanced Research and Diagnostic Laboratory, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States of America.
Naji YounesThe Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Paula McGeeThe Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Claire LundThe Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Mary JohnsonInternational Diabetes Center, Health Partners Institute, Minneapolis, MN, United States of America.
Gayle LorenziUniversity of California, San Diego, La Jolla, CA, United States of America.
Xiaoyu GaoThe Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.ORCID 0000-0003-0633-8996
Michael W SteffesAdvanced Research and Diagnostic Laboratory, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States of America.
John M LachinThe Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
GRADE Research Group
DCCT/EDIC Research Group
Milken Institute · USUniversity of Minnesota · USHarvard University · USHealthPartners · USUniversity of California San Diego · US

Funding

Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) StudyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Heidi Krause-Steinrauf, JOHN M LACHIN · 2021 to 2022
$21.0M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · 1986 to 2025
$12.6M
Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR002243 · VANDERBILT UNIVERSITY MEDICAL CENTER · 2025 to 2025
$10.7M
Washington University Institute of Clinical and Translational SciencesUL1TR002345 · WASHINGTON UNIVERSITY · 2025 to 2025
$9.3M
Georgia Clinical & Translational Science Alliance (Georgia CTSA)UL1TR002378 · EMORY UNIVERSITY · 2025 to 2025
$9.3M
Epidemiology of Diabetes Interventions and Complications (EDIC) StudyU01DK094157 · CASE WESTERN RESERVE UNIVERSITY · 2025 to 2025
$8.0M
Pilot and Feasibility ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 to 2025
$4.9M
Continuation of Epidemiology of Diabetes Interventions and Complications (EDIC) Study Biostatistics CenterU01DK094176 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Ionut Bebu, Barbara Halina Braffett · 2022 to 2022
$4.3M
Louisiana Clinical and Translational Science CenterU54GM104940 · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · 2025 to 2025
$3.9M
NYR-Diabetes Research Center (NYR-DRC)P30DK020541 · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2025 to 2025
$2.4M
Pilot and Feasibility ProgramP30DK072476 · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · 2005 to 2025
$2.2M
UAB Diabetes Research CenterP30DK079626 · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2025 to 2025
$1.3M
NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001108NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001449NCATS NIH HHS UL1 TR002243NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002378NCATS NIH HHS UL1 TR002489NCATS NIH HHS UL1 TR002529NCATS NIH HHS UL1 TR002535NCATS NIH HHS UL1 TR002537NCATS NIH HHS UL1 TR002548NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK020541NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK072476NIDDK NIH HHS P30 DK079626NIDDK NIH HHS P30 DK092926NIDDK NIH HHS U01 DK094157NIDDK NIH HHS U01 DK094176NIDDK NIH HHS U01 DK098246NIDDK NIH HHS U34 DK088043NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

backgroundWe compared HbA1c values obtained from capillary blood collection kits versus venous whole blood collections in study participants with type 1 or type 2 diabetes.

methodsA total of 122 subjects, 64 with type 2 diabetes participating in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study and 58 with type 1 diabetes from the Epidemiology of Diabetes Interventions and Complications (EDIC) Study, participated in the validation study. Capillary tubes were filled by fingerstick by the participants on the same day as the collection of venous whole blood samples in EDTA-containing test tubes and were mailed to the central laboratory. HbA1c in all samples was measured with the same high-performance liquid chromatography. GRADE participants also completed a questionnaire on the ease of performing capillary collections.

resultsParticipants from 22 clinical centers (GRADE n = 5, EDIC n = 17) were between 35 and 86 years of age, with 52% male and diverse race/ethnicities. Venous HbA1c results ranged between 5.4-11.9% (35.5-106.6 mmol/mol) with corresponding capillary results ranging between 4.2-11.9% (22.4-106.6 mmol/mol). The venous and capillary results were highly correlated (R2 = 0.993) and 96.7% differed by ≤0.2% (2.2 mmol/mol). Of participants surveyed, 69% indicated that the instructions and collection were easy to follow and 97% felt the collection method would be easy to do at home.

conclusionsThe capillary blood HbA1c results compared well with the conventional venous whole blood results. The capillary kits can be employed in other studies to reduce interruption of critical data collection and potentially to augment clinical care when in-person visits are not possible.

Indexed as

AdultAgedAged, 80 and overBlood GlucoseBlood Specimen CollectionCapillariesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansMaleMiddle AgedBlood GlucoseGlycated Hemoglobin

Identifiers

PMID34780485
PMCPMC8592405
OpenAlexW3211708690

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.